Table 1.
Baseline patient and disease characteristics
| Total (n = 155) | Screening cohort (n = 58) | Validation cohort (n = 97) | p | |
|---|---|---|---|---|
| Age in years median (IQR) | 60.50 (50.26, 68.49) | 63.46 (50.32, 72.01) | 59.69 (50.24, 67.84) | 0.125 |
| Sex, n (%) | 0.32 | |||
| female | 69 (45) | 29 (51) | 40 (41) | |
| male | 85 (55) | 28 (49) | 57 (59) | |
| WBC 109/L (n = 152) median (IQR) | 5.30 (2.05, 25.80) | 4.70 (1.70, 19.80) | 5.85 (2.50, 33.02) | 0.325 |
| PB blast % (n = 141) median (IQR) | 21.50 (4.00, 53.50) | 16.00 (4.00, 53.00) | 23.00 (4.50, 54.00) | 0.535 |
| BM blast % (n = 146) median (IQR) | 63.00 (40.00, 80.00) | 60.00 (41.50, 80.50) | 70.00 (40.25, 80.00) | 0.507 |
| Cytogenetics, (n = 135) | ||||
| CN-AML, n (%) | 56 (42) | 21 (42) | 35 (42) | 1 |
| complex.karyotype, n (%) | 26 (19) | 9 (18) | 17 (20) | 0.927 |
| t(11q23), n (%) | 8 (6) | 3 (6) | 5 (6) | 1 |
| del(5q)/-5, n (%) | 5 (4) | 1 (2) | 4 (5) | 0.65 |
| inv(3)/t(3;3), n (%) | 2 (1) | 1 (2) | 1 (1) | 1 |
| other, n (%) | 37 (28) | 15 (30) | 22 (26) | 0.782 |
| Mutated RUNX1, n (%) | 32 (21) | 15 (27) | 17 (18) | 0.239 |
| Mutated IDH1, n (%) | 12 (8) | 5 (9) | 7 (7) | 0.758 |
| Mutated IDH2, n (%) | 22 (15) | 10 (18) | 12 (13) | 0.492 |
| Mutated DNMT3A, n (%) | 26 (17) | 16 (29) | 10 (10) | 0.007 |
| Mutated ASXL1, n (%) | 23 (17) | 8 (16) | 15 (18) | 0.969 |
| Mutated TP53, n (%) | 14 (10) | 6 (12) | 8 (9) | 0.854 |
WBC white blood cell count, PB blast peripheral blood blast count, BM blast, bone marrow blast count, CEBPA, CCAAT/ enhancer-binding protein alpha, DNMT3A DNA methyltransferase 3A, ASXL1 additional sex combs-like 1, RUNX1 runt-related transcription factor 1, IDH Isocitrate dehydrogenase, TP53 tumor protein P53